374 related articles for article (PubMed ID: 33176880)
1. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M
Law WY; Asaruddin MR; Bhawani SA; Mohamad S
BMC Res Notes; 2020 Nov; 13(1):527. PubMed ID: 33176880
[TBL] [Abstract][Full Text] [Related]
2. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
3. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
[TBL] [Abstract][Full Text] [Related]
4. GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Hattori SI; Higshi-Kuwata N; Raghavaiah J; Das D; Bulut H; Davis DA; Takamatsu Y; Matsuda K; Takamune N; Kishimoto N; Okamura T; Misumi S; Yarchoan R; Maeda K; Ghosh AK; Mitsuya H
mBio; 2020 Aug; 11(4):. PubMed ID: 32820005
[TBL] [Abstract][Full Text] [Related]
5. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
6. Theoretical Insights into the Anti-SARS-CoV-2 Activity of Chloroquine and Its Analogs and In Silico Screening of Main Protease Inhibitors.
Achutha AS; Pushpa VL; Suchitra S
J Proteome Res; 2020 Nov; 19(11):4706-4717. PubMed ID: 32960061
[TBL] [Abstract][Full Text] [Related]
7. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
8. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
9. Discovery of alliin as a putative inhibitor of the main protease of SARS-CoV-2 by molecular docking.
Cheng B; Li T
Biotechniques; 2020 Aug; 69(2):108-112. PubMed ID: 32459144
[TBL] [Abstract][Full Text] [Related]
10. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection.
Fantini J; Di Scala C; Chahinian H; Yahi N
Int J Antimicrob Agents; 2020 May; 55(5):105960. PubMed ID: 32251731
[TBL] [Abstract][Full Text] [Related]
11. 2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease.
Forrestall KL; Burley DE; Cash MK; Pottie IR; Darvesh S
Chem Biol Interact; 2021 Feb; 335():109348. PubMed ID: 33278462
[TBL] [Abstract][Full Text] [Related]
12. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M
Abu-Melha S; Edrees MM; Riyadh SM; Abdelaziz MR; Elfiky AA; Gomha SM
Molecules; 2020 Oct; 25(19):. PubMed ID: 33036293
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds.
Liu P; Liu H; Sun Q; Liang H; Li C; Deng X; Liu Y; Lai L
Eur J Med Chem; 2020 Nov; 206():112702. PubMed ID: 32798789
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation.
Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA
J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618
[TBL] [Abstract][Full Text] [Related]
15. New Anti SARS-Cov-2 Targets for Quinoline Derivatives Chloroquine and Hydroxychloroquine.
Gentile D; Fuochi V; Rescifina A; Furneri PM
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824072
[TBL] [Abstract][Full Text] [Related]
16. Investigation of Some Antiviral
Hagar M; Ahmed HA; Aljohani G; Alhaddad OA
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486229
[TBL] [Abstract][Full Text] [Related]
17. Alkamides and Piperamides as Potential Antivirals against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Gutierrez-Villagomez JM; Campos-García T; Molina-Torres J; López MG; Vázquez-Martínez J
J Phys Chem Lett; 2020 Oct; 11(19):8008-8016. PubMed ID: 32840378
[TBL] [Abstract][Full Text] [Related]
18. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
19. Signal amplification by reversible exchange for COVID-19 antiviral drug candidates.
Jeong HJ; Min S; Chae H; Kim S; Lee G; Namgoong SK; Jeong K
Sci Rep; 2020 Aug; 10(1):14290. PubMed ID: 32868801
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
Kang CK; Seong MW; Choi SJ; Kim TS; Choe PG; Song SH; Kim NJ; Park WB; Oh MD
Korean J Intern Med; 2020 Jul; 35(4):782-787. PubMed ID: 32460458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
